Parkinson's Disease Clinical Trial
Official title:
Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes
The purpose of this study is to gather observational data on an already FDA-approved implantation technique for deep brain stimulation (DBS) in which the entire surgery is performed within an MRI scanner ("interventional MRI", or iMRI). With this surgical technique, the patient is fully asleep (under general anesthesia) during DBS implantation. The standard method for the placement of deep brain stimulators does not use MRI during the actual DBS placement. The standard method involves placement of a rigid frame on the patient's head, performance of a short MRI scan, transport to the operating room, placement of the DBS electrodes in the operating room, and return to the MRI suite for another MR to confirm correct electrode placement. In the standard method, the patient must be awake for 2-4 hours in the operating room to have "brain mapping" performed, where the brain target is confirmed by passing "microelectrodes" (thin wires) into the brain to record its electrical activity. In the standard method, general anesthesia is not required. With the iMRI technique, the surgery is guided entirely by MRI images performed multiple times as the DBS electrode is advanced. This eliminates the need for the patient to be awake, and eliminates the need for passing microelectrodes into the brain before placing the permanent DBS electrode.
Deep brain stimulation (DBS) is an increasingly common surgical technique for the treatment
of Parkinson's disease and dystonia. The current technical approach to DBS implantation
involves frame-based stereotaxy. In this method, a stereotactic frame is rigidly fixed to the
patient's skull, an MRI is obtained, an anatomic target is identified, and the coordinates of
the target in stereotactic space are calculated. Instruments are mounted on the stereotactic
frame that point to the calculated coordinate. However, due to the inherent inaccuracies in
standard frame-based stereotaxy, a complex 6-hour procedure then ensues to "map" the brain
target with microelectrodes, place the lead, and return to the MR unit to confirm proper
placement.
The goal of this project is to gather observational data on the iMRI DBS implantation
technique and clinical outcomes. This already FDA-approved implantation technique for DBS
will take place entirely within the Phillips 1.5T and a Siemens 3T open magnet MRI machine.
Prior to study initiation, instrumentation and MR protocols were tested using a phantom head.
In the proposed project, subthalamic nucleus or globus pallidus DBS implantations will be
performed bilaterally in patients with Parkinson's disease or dystonia. Patients will be
under general anesthesia. Targeting and lead verification are performed with imaging alone,
without physiologic mapping. Data is to be gathered on the following: operative time, degree
of benefit with bilateral implantation (changes in standard rating scales of motor
disability), DBS voltage requirements, complications), and electrode location by MR. These
measures will be compared with our historical controls, previously entered into our research
database, in which electrodes were placed by the standard methods. We expect that the use of
near real time MR will improve the speed and accuracy of DBS implantation, and eliminate the
need for invasive physiological monitoring.
All of the study participants will be getting iMRI DBS implantation as a part of their
standard of care and agree to have additional study data collected
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |